血液透析滤过与高通量血液透析对β2微球蛋白的动力学影响
基于两池动力学模型,利用HEMO研究等数据,模拟血液透析滤过(HDF)与高通量血液透析对β2微球蛋白(β2M)清除与生成的影响。模型预测透析前及时间平均β2M水平与实测值一致,HDF仅小幅降低β2M,残余肾功能影响显著。
要点
- HDF对透析前和时间平均β2M的降低作用相对较小
- 残余肾功能是透析前和时间平均β2M水平的主要决定因素
- 两池动力学模型可较好地预测不同透析方案下的β2M水平
核心结论
- 两池动力学模型预测的β2M下降率和透析前浓度与多种HDF和HD方案的实测值一致。
- HDF对降低透析前或时间平均β2M水平的影响相对较小,残余肾功能影响显著。
研究设计与样本
- 研究采用β2M清除与生成的动力学模型,在HEMO研究数据及高通量血液透析患者样本中测试。
- 通过模拟四项比较HDF与HD的随机研究评估HDF对β2M的影响,并比较残余肾功能影响的模型预测与已发表实测数据。
主要发现
- HEMO低通量和高通量组的中位β2M下降率分别与透析器清除率5.9和29 ml/min匹配,中位透析前β2M水平在生成率约235 mg/d时匹配。
- 在另一组使用高β2M清除透析器的患者中,实测跨透析器清除率为57±28 ml/min,模型估计的透析中和透析后早期β2M水平与中位实测值相似。
- 模型能估计四项HDF与HD随机比较中透析前β2M的变化,但预测的HDF降低幅度大于其中两项研究报告值。
- 模型预测残余肾清除对透析前β2M浓度的影响与一项已发表观察性研究相似。
- 模型预测使用25 L/4小时置换液的后稀释HDF可使β2M时间平均浓度降低约18.2%,与残余肾GFR 1.50 ml/min的效果相似。
临床怎么用
- 临床可参考两池动力学模型评估不同透析模式对β2M的清除效果。
- 对于残余肾功能较好的患者,HDF额外降低β2M的获益可能有限。
局限性
- 模型预测HDF降低透析前β2M的幅度大于两项随机研究报告值,提示模型可能存在高估。
- 残余肾功能影响的预测仅与一项观察性研究比较,验证有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Addition of hemodiafiltration has a relatively small impact on reducing either predialysis or time-averaged serum β-2-microglobulin levels. Residual kidney function has a major impact on the predialysis and time-averaged serum β-2-microglobulin levels. BACKGROUND: A kinetic model for β-2-microglobulin removal and generation was used to explore the impact of adding hemodiafiltration on predialysis and time-averaged serum values. METHODS: The model was tested on data from the HEMO study and on a sample of patients undergoing high-flux hemodialysis. The impact of hemodiafiltration on β-2-microglobulin levels was evaluated by modeling four randomized studies of hemodiafiltration versus hemodialysis. The impact of residual kidney function on β-2-microglobulin was tested by comparing results of previously reported measured data with model predictions. RESULTS: In the low-flux and high-flux arms of the HEMO study, measured median β-2-microglobulin reduction ratios could be matched by dialyzer clearances of 5.9 and 29 ml/min, respectively. Median predialysis serum β-2-microglobulin levels were matched if generation rates of β-2-microglobulin were set to approximately 235 mg/d. In another group of patients treated with dialyzers with increased β-2-microglobulin clearances, measured cross-dialyzer clearances (57±28 ml/min) were used as inputs. In these studies, the kinetic model estimates of intradialysis and early postdialysis serum β-2-microglobulin levels were similar to median measured values. The model was able to estimate the changes in predialysis serum β-2-microglobulin in each of four published randomized comparisons of hemodiafiltration with hemodialysis, although the model predicted a greater decrease in predialysis serum β-2-microglobulin with hemodiafiltration than was reported in two of the studies. The predicted impact of residual kidney clearance on predialysis serum β-2-microglobulin concentrations was similar to that reported in one published observational study. Modeling predicted that postdilution hemodiafiltration using 25 L/4 hours replacement fluid would lower serum time-averaged concentration of β-2-microglobulin by about 18.2%, similar to the effect of 1.50 ml/min residual kidney GFR. CONCLUSIONS: A two-pool kinetic model of β-2-microglobulin yielded values of reduction ratio and predialysis serum concentration that were consistent with measured values with various hemodiafiltration and hemodialysis treatment regimens.
引用
- Ward RA, Daugirdas JT. Kinetics of β -2-Microglobulin with Hemodiafiltration and High-Flux Hemodialysis. Clin J Am Soc Nephrol. 2024. PMID: 38650079. doi:10.2215/CJN.0000000000000461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。